Systemic insulin-like growth factor-1 reverses hypoalgesia and improves mobility in a mouse model of diabetic peripheral neuropathy

Molecular Therapy

Volumn 16, Issue 8, 2008, Pages 1400-1408

  Chu, Qiuming ^a   Moreland, Rod ^a   Yew, Nelson S ^a   Foley, Joseph ^a   Ziegler, Robin ^a   Scheule, Ronald K ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; PARVOVIRUS VECTOR; PLASMID VECTOR; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VACUOLE; CONTROLLED STUDY; DEMYELINATION; DIABETIC NEUROPATHY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; GENE THERAPY; HYPERALGESIA; HYPOALGESIA; LIVER; LOW DRUG DOSE; MALE; MOTOR PERFORMANCE; MOUSE; MUSCLE ATROPHY; MUSCLE WEAKNESS; NERVE CONDUCTION; NONHUMAN; PHYSICAL MOBILITY; SCHWANN CELL; SENSORY NERVE; STREPTOZOCIN DIABETES;

ANIMALS; BODY WEIGHT; DEPENDOVIRUS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DISEASE MODELS, ANIMAL; GENE THERAPY; GENETIC VECTORS; HYPERALGESIA; INSULIN-LIKE GROWTH FACTOR I; LIVER; MALE; MICE; MICE, INBRED C57BL; MOTOR NEURONS;

MUS; RODENTIA;

EID: 48349133827     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.115     Document Type: Article

References (44)

1. Gordois, A, Scuffham, P, Shearer, A, Oglesby, A and Tobian, JA (2003). The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 26: 1790-1795.
2. Rathur, HM and Boulton, AJ (2007). The neuropathic diabetic foot. Nat Clin Pract Endocrinol Metab 3: 14-25.
3. Frier, BM (2004). Morbidity of hypoglycemia in type 1 diabetes. Diabetes Res Clin Pract 65: S47-S52.
4. Mohseni, S (2001). Hypoglycemic neuropathy. Acta Neuropathol 102: 413-421.
5. Leinninger, GM, Vincent AM and Feldman, EL (2004). The role of growth factors in diabetic peripheral neuropathy. J Peripher Nerv Syst 9: 26-53.
6. Apfel, SC, Schwartz, S, Adomato, BT, Freeman, R, Biton, V, Rendell, M et al. (2000). Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 284: 2215-2221.
7. Wellmer, A, Misra, VP, Sharief, MK, Kopelman, PG and Anand, P (2001). A double-blind placebo-controlled clinical trial of recombinant human brain-derived neurotrophic fartor (rhBDNF) in diabetic polyneuropathy. J Peripher Nerv Syst 6: 204-210.
8. Isner, JM, Ropper, A and Hirst, K (2001). VEGF gene transfer for diabetic neuropathy. Hum Gene Ther 12:1593-1594.
9. Ekberg, K, Brismar, T, Johansson, BL, Lindström, P, Juntti-Berggren, L, Norrby, A et al. (2007). C-peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care 30: 71-76.
10. Guo, H, Yang, Y, Geng, Z, Zhu, L, Yuan, S, Zhao, Y et al. (1999). The change of insulin-like growth factor-1 in diabetic patients with neuropathy. Chin Med J (Engl) 112: 76-79.
11. Migdalis, IN, Kalogeropoulou, K, Kalantzis, L, Nounopoulos, C, Bouloukos, A, and Samartzis, M (1995). Insulin-like growth factor-I and IGF-I receptors in diabetic patients with neuropathy. Diabet Med 12: 823-827.
12. Wilkinson-Berka, JL, Wraight, C and Wertherg (2006). The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy. Curr Med Chem 13: 3307-3317.
13. Slomiany, MG and Rosenzweig, SA (2006). Hypoxia-inducible factor-1-dependent and -independent regulation of insulin-like growth factor-1-stimulated vascular endothelial growth factor secretion. J Pharmacol Exp Ther 318: 666-675.
14. Andreassen, CS, Jakobsen, J and Andersen, H (2006). Muscle weakness: A progressive late complication in diabetic distal symmetric polyneuropathy. Diabetes 55: 806-812.
15. McKay, G, Ashley, W, Mander, J, Yang, SY, Williams, N, Russell, B et al. (1999). Expression of insulin growth factor-1 splice variants and structural genes in rabbit skeletal muscle induced by stretch and stimulation. J Physiol 516: 583-592.
16. Musarò, A, McCullagh, K, Paul, A, Houghton, L, Dobrowolny, G, Molinaro, M et al. (2001). Localized lgf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 27: 195-200.
17. Zhuang, HX, Snyder, CK, Pu, SF and Ishii, DN (1996). Insulin-like growth factors reverse or arrest diabetic neuropathy: Effects on hyperalgesia and impaired nerve regeneration in rats. Exp Neurol 140: 198-205.
18. Gao, WQ, Shinsky, N, Ingle, G, Beck, K, Elias, KA and Powell-Braxton, L (1999). IGF-I deficient mice show reduced peripheral nerve conduction velocities and decreased axonal diameters and respond to exogenous IGF-I treatrnent. J Neurobiol 39: 142-152.
19. Schmidt, RE, Dorsey, DA, Beaudet LN, Plurad, SB, Parvin, CA and Miller ms (1999). Insulin-like growth factor I reverses experimental diabetic autonomic neuropathy. Am J Pathol 155: 1651-1660.
20. Han, HJ and Park, SH (2006). Alteration of the gene and protein levels of insulin-like growth factors in streptozotocin-induced diabetic male rats. I Vet Med Sci 68: 413-419.
21. Bitar, ms, Pitcher, CW, Khan, I and Waldbillig, RJ (1997). Diabetes-induced suppression of IGF-l and its receptor mRNA levels in rat superior cervical ganglia. Diabetes Res Clin Pract 38: 73-80.
22. Zhao AZ, Zhao, H, Teague, J, Fujimoto, W and Beavo, JA (1997). Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B. Proc Nod Acad Sci USAb 94: 3223-3228.
23. Grandis, M, Nobbio, L, Abbruzzese, M, Banchi, L, Minuto, F, Barreca, A et al. (2001). insulin treatment enhances expression of IGF-1 in sural nerves of diabetic patients. Muscle Nerve 24: 622-629.
24. Schmidt RE, Dorsey, DA Beaudet, LN and Peterson, RG (2003). Analysis of the Zucker diabetic fatty (ZDF) type 2 diabetic rat model suggests a neurotrophic role for insulin/IGF-I in diabetic autonomic neuropathy. Am J Pathol 163: 21-28.
25. Mohseni, S and Hildebrand, C (1998). Neuropathy in diabetic BB/Wor rats treated with insulin implants. Acta Neuropathol 96: 144-150.
26. George, M, Ayuso, E, Casellas, A, Costa, C, Devedjian, JC and Bosch, F (2002). Beta cell expression of IGF-I leads to recovery from type 1 diabetes. J Clin Invest 109: 1153-1163.
27. Kalichman, MW, Powell, HC and Mizisin, AP (1998). Reactive, degenerative, and proliferative Schwann cell responses in experimental galactose and human diabetic neuropathy. Acta Neuropathol 95 47-56.
28. Srinivasan, S, Stevens, M and Wiley, JW (2000). Diabetic peripheral neuropathy: Evidence for apoptosis and associated mitochondrial dysfunction. Diabetes 49: 1932-1938.
29. Vinik, AI (2003). Management of neuropathy and foot problems in diabetic patients. Clin Cornerstone 5: 38-55.
30. Russell, JW, Cheng, HL and Golovoy, D (2000). Insulin-like growth factor-1 promotes myelination of peripheral sensory axons. J Neuropathol Exp Neurol 59: 575-584.
31. Delaney, CL, Russell, JW, Cheng, HL and Feldman, EL (2001). Insulin-like growth factor-1 and over-expression of Bcl-xL prevent glucose-mediated apoptosis in Schwann cells. J Neuropathol Exp Neurol 60: 147-160.
32. Cheng, HL, Russell, JW and Feldman, EL (1999). IGF-I promotes peripheral nervous system myelination. Ann NY Acad Sci 883: 124-130.
33. Ye, P, Li, L, Lund, PK and D'Ercole, AL (2002). Deficient expression of insulin receptor substrate-1 (IRS-1) fails to block insulin-like growth factor-1 (IGF-1) stimulation of brain growth and myelination. Brain Res Dev Brain Res 136: 111-121.
34. Mason, JL, Xuan, S, Dragatsis, I, Efstratiadis, A and Goldman, JE (2003). Insulin-like growth factor (IGF) signaling through type 1 IGF receptor plays an important role in remyelination. J Neurosci 23: 7710-7718.
35. Stewart, HJ, Bradke, F, Tabemero, A, Morrell, D, Jessen, KR and Mirsky, R (1996). Regulation of rat Schwann cell Po expression and DNA synthesis by insulin-like growth factors in vitro. Eur J Neurosci: 8 553-564.
36. Steer, JM (1971). Some observations on the fine structure of rat dorsal spinal nerve roots. J Anat 109: 467-485.
37. Wu, Y, Zhao, W, Zhao, J, Pan, J, Wu, Q, Zhang, Y et al. (2007). Identification of androgen response elements in the insulin-like growth factor 1 upstream promoter. Endocrinology 148: 2984-2993.
38. Chu, Q, Joseph, M, Przybylska, M, Yew, NS and Scheule, RK (2005). Transient siRNA-mediated attenuation of liver expression from an alpha-galactosidase A plasmid reduces subsequent humoral immune responses to the transgene product in mice. Mol Ther 12: 264-273.
39. Laughlin, CA, Tratschin, JD, Coon, H and Carter, BJ (1983). Cloning of infectious adeno-associated virus genomes in bacterial plasmids. Gene 23: 65-73.
40. Zolotukhin, S, Byme, BJ, Mason, E, Zolotukhin, I, Potter, M, Chesnut, K et al (1999). Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6: 973-985.
41. Zhang, G, Budker, V and Wolff, JA (1999). High Lewis of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 10: 1735-1737
42. Liu, F, Song, Y and Liu, D (1999). Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther: 6 1258-1266.
43. Puccio, H, Simon, D, Cossée M, Criqui-Filipe, P, Tiziano, F, Melki, J et al. (2001). Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet 27: 181-186.
44. Sleat, DE, Wiseman, JA, El-Banna, M, Kim, KH, Mao, Q, Price, S et al. (2004). A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegeneration. J Neurosci 24: 9117-9126.